Recombinant Deoxyribonucleic Acid Rdna Technology Market
Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Forecasts to 2028 – Global Analysis By Component (Cloning Vector, Expression System), Application (Food & Beverages, Agriculture, Therapeutics) and By Geography
|
Years Covered |
2020-2028 |
|
Estimated Year Value (2021) |
US $155.79 BN |
|
Projected Year Value (2028) |
US $301.67 BN |
|
CAGR (2021 - 2028) |
9.9% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market is accounted for $155.79 billion in 2021 and is expected to reach $301.67 billion by 2028 growing at a CAGR of 9.9% during the forecast period. Recombinant DNA technology is a process in which creation and manipulation of the DNA sequences are in a specific order. This is resulting in the production of genetically modified organisms and products. Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals.
Market Dynamics:
Driver:
Rising demand from various industries
Many industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied.
Restraint:
Risk associated with gene therapy
The global recombinant DNA technology market might face major restraints due to the risk associated with gene therapy. Another major restraint can be the stringent regulation for the approval of the product in various regions.
Opportunity:
Growth of genetic testing
In the North American and Western European regions, the genetic testing market grows larger, spreading its hands to many remote areas. Therefore, this can bring more opportunities for the service providers and companies to make the tests more affordable. Along with that, the global Recombinant DNA Technology Market is trying to enter the untapped regions to bring lucrative opportunities.
Threat:
Ethical considerations
The use of genetic modification technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and environment, scientific and ethical concerns vary in a discipline-specific manner.
The expression system segment is expected to be the largest during the forecast period
Expression systems captured the largest share owing to the ongoing developments for efficient protein expression and for its further isolation on a large scale. Majorly used expression systems are mammalian, bacterial, insects, and yeast. The development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed to the significant share of mammalian expression systems. In addition, ongoing research studies to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years.
The agriculture segment is expected to have the highest CAGR during the forecast period
In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing a widespread adoption.
Region with largest share:
North America is projected to hold the largest market share owing to the substantial number of biopharmaceutical manufacturing participants which are headquartered in the U.S. The presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology has also driven the regional growth. For instance, this country witnessed the 1st FDA approval for U.S. gene therapy treatment. The treatment was developed for leukemia, as a result of a collaboration between the University of Pennsylvania and Novartis Corp. This, in turn, is anticipated to nurture the implementation of rDNA techniques in the region.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR due to the presence of low-cost manufacturing centers in the Asian economies, such as China. Japan is recognized as one of the world’s largest per capita importers of food and feed developed using modern biotechnology tools. Japan’s regulatory system for GE crops continues to improve. Moreover, there is no significant trade barrier in Japan to hamper GE products export from western countries. As a result, Asia Pacific is expected to emerge as the fastest-growing regional market.
Key players in the market
Some of the key players profiled in the Recombinant Deoxyribonucleic Acid (rDNA) Technology Market include Novartis AG, GlaxoSmithKline plc., Sanofi SA, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., Thermo Fisher Scientific, Inc., Biogen Inc., Biocon Limited, Novo Nordisk A/S, Merck KGaA, Amgen Inc., Boehringer Ingelheim, Chiron Corporation, Genscript Biotech, Horizon Discovery Group plc, Monsanto Company, and Profacgen.
Key developments:
In January 2022: Pfizer and Beam entered exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases. Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies.
In July 2020: GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.
Components Covered:
• Cloning Vector
• Expression System
Products Covered:
• Medical
• Non-Medical
Applications Covered:
• Food & Beverages
• Agriculture
• Therapeutics
• Healthcare & Disease
• Environment
End Users Covered:
• Biotechnology and Pharmaceutical Companies
• Diagnostic Laboratories
• Academic & Government Research Institutes
• Biochemical Industry
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Component
5.1 Introduction
5.2 Cloning Vector
5.2.1 Human Artificial Chromosome (HAC)
5.2.2 Yeast Artificial Chromosome (YAC)
5.2.3 Bacterial Artificial Chromosome (BAC)
5.2.4 Cosmid
5.2.5 Plasmid
5.2.6 Phage
5.3 Expression System
5.3.1 Mammalian Cells
5.3.2 Prokaryotic Cells
5.3.3 Bacteria
5.3.4 Yeast
5.3.5 Baculovirus / Insect
6 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Product
6.1 Introduction
6.2 Medical
6.2.1 Therapeutic Agent
6.2.2 Vaccine
6.2.3 Human Protein
6.2.4 Gene Editing
6.2.5 Cell and Gene Therapy
6.2.6 Monoclonal Antibodies
6.2.7 Recombinant Protein Drugs
6.2.7.1 Human Growth Hormone
6.2.7.2 Blood Factors
6.2.7.3 Colony Stimulating Factors
6.2.7.4 Erythropoietin
6.2.7.5 Fusion Proteins
6.2.7.6 Interferon
6.2.7.7 Insulin
6.3 Non-Medical
6.3.1 Genetically Modified Crops
6.3.2 Specialty Chemicals
6.3.3 Biotech Crops
7 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Application
7.1 Introduction
7.2 Food & Beverages
7.3 Agriculture
7.4 Therapeutics
7.5 Healthcare & Disease
7.5.1 Human
7.5.2 Animal
7.6 Environment
8 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By End User
8.1 Introduction
8.2 Biotechnology and Pharmaceutical Companies
8.3 Diagnostic Laboratories
8.4 Academic & Government Research Institutes
8.5 Biochemical Industry
9 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Novartis AG
11.2 GlaxoSmithKline plc.
11.3 Sanofi SA
11.4 F. Hoffmann-La Roche Ltd
11.5 Eli Lilly and Company
11.6 Pfizer Inc.
11.7 Thermo Fisher Scientific, Inc.
11.8 Biogen Inc.
11.9 Biocon Limited
11.10 Novo Nordisk A/S
11.11 Merck KGaA
11.12 Amgen Inc.
11.13 Boehringer Ingelheim
11.14 Chiron Corporation
11.15 Genscript Biotech
11.16 Horizon Discovery Group plc
11.17 Monsanto Company
11.18 Profacgen
List of Tables
1 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Region (2020-2028) ($MN)
2 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Component (2020-2028) ($MN)
3 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cloning Vector (2020-2028) ($MN)
4 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human Artificial Chromosome (HAC) (2020-2028) ($MN)
5 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Yeast Artificial Chromosome (YAC) (2020-2028) ($MN)
6 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Bacterial Artificial Chromosome (BAC) (2020-2028) ($MN)
7 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cosmid (2020-2028) ($MN)
8 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Plasmid (2020-2028) ($MN)
9 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Phage (2020-2028) ($MN)
10 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Expression System (2020-2028) ($MN)
11 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Mammalian Cells (2020-2028) ($MN)
12 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Prokaryotic Cells (2020-2028) ($MN)
13 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Bacteria (2020-2028) ($MN)
14 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Yeast (2020-2028) ($MN)
15 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Baculovirus / Insect (2020-2028) ($MN)
16 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Product (2020-2028) ($MN)
17 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Medical (2020-2028) ($MN)
18 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Therapeutic Agent (2020-2028) ($MN)
19 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Vaccine (2020-2028) ($MN)
20 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human Protein (2020-2028) ($MN)
21 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Gene Editing (2020-2028) ($MN)
22 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cell and Gene Therapy (2020-2028) ($MN)
23 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Monoclonal Antibodies (2020-2028) ($MN)
24 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Recombinant Protein Drugs (2020-2028) ($MN)
25 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Non-Medical (2020-2028) ($MN)
26 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Genetically Modified Crops (2020-2028) ($MN)
27 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Specialty Chemicals (2020-2028) ($MN)
28 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biotech Crops (2020-2028) ($MN)
29 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Application (2020-2028) ($MN)
30 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Food & Beverages (2020-2028) ($MN)
31 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Agriculture (2020-2028) ($MN)
32 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Therapeutics (2020-2028) ($MN)
33 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Healthcare & Disease (2020-2028) ($MN)
34 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human (2020-2028) ($MN)
35 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Animal (2020-2028) ($MN)
36 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Environment (2020-2028) ($MN)
37 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By End User (2020-2028) ($MN)
38 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biotechnology and Pharmaceutical Companies (2020-2028) ($MN)
39 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
40 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Academic & Government Research Institutes (2020-2028) ($MN)
41 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biochemical Industry (2020-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
